Ani Pharmaceuticals (ANIP) Cash from Operations Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 27.85% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 39.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.67% |
| Dec 31, 2025 | 107.25% |
| Sep 30, 2025 | 129.95% |
| Jun 30, 2025 | 104.89% |
| Mar 31, 2025 | 56.69% |
| Dec 31, 2024 | 48.90% |
| Sep 30, 2024 | 62.73% |
| Jun 30, 2024 | 316.51% |
| Mar 31, 2024 | -4.03% |
| Dec 31, 2023 | 114.26% |
| Sep 30, 2023 | 179.91% |
| Jun 30, 2023 | -0.41% |
| Mar 31, 2023 | 132.26% |
| Dec 31, 2022 | -42.87% |
| Sep 30, 2022 | -45.01% |
| Jun 30, 2022 | -64.12% |
| Mar 31, 2022 | -49.26% |
| Dec 31, 2021 | -34.76% |
| Sep 30, 2021 | -38.37% |
| Jun 30, 2021 | -69.62% |